Pre-S1_JJ Antigen-Dependent_JJ Infection_NN of_IN Tupaia_NP Hepatocyte_NP Cultures_NP with_IN Human_NP Hepatitis_NP B_NP Virus_NP The_DT susceptibility_NN of_IN the_DT tree_NN shrew_NN Tupaia_NP belangeri_NP to_TO human_JJ hepatitis_NP B_NP virus_NN (_( HBV_NP )_) has_VBZ been_VBN demonstrated_VBN both_CC in_IN vivo_JJ and_CC in_IN vitro_NN ._SENT In_IN this_DT study_NN ,_, we_PP show_VBP that_IN purified_VBN HBV_NP infects_VBZ primary_JJ T._NP belangeri_NN hepatocyte_NN cultures_NNS in_IN a_DT very_RB specific_JJ manner_NN ,_, as_RB detected_VBN by_IN HBV_NP covalently_RB closed_VBD circular_JJ DNA_NN ,_, mRNA_NP ,_, HBV_NP e_NP antigen_NN ,_, and_CC HBsAg_NP production_NN ._SENT A_DT monoclonal_NN antibody_NN (_( MAb_NP )_) ,_, MA18/7_JJ ,_, directed_VBN against_IN the_DT pre-S1_JJ domain_NN of_IN the_DT large_JJ HBs_NP protein_NN ,_, which_WDT has_VBZ been_VBN shown_VBN to_TO neutralize_VB infectivity_NN of_IN HBV_NP for_IN primary_JJ human_JJ hepatocytes_NNS ,_, also_RB blocked_VBN infection_NN of_IN primary_JJ Tupaia_NP hepatocytes_NNS ._SENT MAbs_NNS against_IN the_DT pre-S2_JJ domain_NN of_IN HBs_NP inhibited_VBD infection_NN only_RB partially_RB ,_, whereas_IN an_DT S_NP MAb_NP and_CC polyvalent_JJ anti-HBs_NNS antibodies_NNS neutralized_VBD infection_NN completely_RB ._SENT Thus_RB ,_, both_DT pre-S1_NN and_CC S_NN antigens_NNS are_VBP necessary_JJ for_IN infection_NN in_IN the_DT tupaia_NP ._SENT Using_VBG subviral_JJ particles_NNS ,_, >70_JJ %_NN of_IN primary_JJ Tupaia_NP hepatocytes_NNS are_VBP capable_JJ of_IN specific_JJ binding_NN of_IN pre-S1-rich_NP HBsAg_NP ,_, showing_VBG localization_NN in_IN distinct_JJ membrane_NN areas_NNS ._SENT The_DT data_NNS show_VBP that_IN the_DT early_JJ steps_NNS of_IN HBV_NP infection_NN in_IN Tupaia_NP hepatocyte_NN cultures_NNS are_VBP comparable_JJ to_TO those_DT in_IN the_DT human_JJ system_NN ._SENT Persistent_JJ infection_NN with_IN hepatitis_NP B_NP virus_NN (_( HBV_NP )_) ,_, a_DT small_JJ enveloped_VBN DNA_NN virus_NN ,_, is_VBZ a_DT frequent_JJ cause_NN of_IN liver_NN cirrhosis_NN and_CC hepatocellular_JJ carcinoma_NN ._SENT With_IN >350_JJ million_CD chronically_RB infected_VBN people_NNS ,_, HBV_NP is_VBZ a_DT major_JJ health_NN problem_NN worldwide_RB ._SENT HBV_NP is_VBZ a_DT member_NN of_IN the_DT Hepadnaviridae_NP ,_, a_DT familiy_NP of_IN hepatotropic_JJ and_CC highly_RB species-specific_JJ viruses_NNS which_WDT are_VBP able_JJ to_TO infect_VB in_IN culture_NN only_RB well-differentiated_VBN primary_JJ hepatocytes_NNS of_IN their_PP$ specific_JJ hosts_NNS ._SENT Human_JJ and_CC related_JJ hepadnaviruses_NNS from_IN higher_JJR primates_NNS (_( Hominoidae_NP )_) are_VBP considered_VBN to_TO form_VB one_CD virus_NN species_NN ,_, HBV_NP (_( ICTVdB_NP :_: The_DT Universal_NP Virus_NP Database_NP of_IN the_DT International_NP Committee_NP on_IN Taxonomy_NP of_IN Viruses_NP [_SYM ._SENT ]_SYM )_) ._SENT Further_RBR ,_, hepadnavirus_NN species_NNS are_VBP found_VBN in_IN woolly_JJ monkeys_NNS (_( Platyrrhini_NP )_) and_CC in_IN woodchucks_NNS and_CC squirrels_NNS (_( both_CC Rodentia_NP )_) and_CC form_VB the_DT genus_NN Orthohepadnavirus_NP (_( ._SENT )_) ._SENT Since_IN HBV_NP naturally_RB infects_VBZ only_JJ humans_NNS and_CC higher_JJR primates_NNS ,_, many_JJ efforts_NNS have_VBP been_VBN made_VBN to_TO establish_VB a_DT small-animal_JJ model_NN for_IN the_DT study_NN of_IN HBV_NP infection_NN (_( reviewed_VBN in_IN reference_NN )_) ._SENT Some_DT mouse-related_JJ models_NNS ,_, like_IN the_DT uPa-mouse_NN or_CC trimera-mouse_NN ,_, use_VBP transplanted_JJ human_JJ hepatocytes_NNS ,_, but_CC they_PP are_VBP difficult_JJ to_TO work_VB with_IN ._SENT Experimental_JJ hepatitis_NN delta_NN virus_NN and_CC HBV_NP infection_NN (_( in_IN 1995_CD and_CC 1996_CD ,_, respectively_RB )_) of_IN a_DT small_JJ animal_NN ,_, the_DT tupaia_NP ,_, have_VBP been_VBN reported_VBN ._SENT These_DT mammals_NNS ,_, also_RB called_VBN tree_NN shrews_NNS ,_, are_VBP found_VBN in_IN tropical_JJ forests_NNS of_IN Southeast_NP Asia_NP ._SENT In_IN contrast_NN to_TO previous_JJ assumptions_NNS ,_, they_PP are_VBP not_RB primordial_JJ primates_NNS but_CC form_VB their_PP$ own_JJ order_NN ,_, Scandentia_NP ,_, in_IN the_DT family_NN Tupaiidae_NNS ._SENT Tupaias_NNS can_MD be_VB infected_VBN experimentally_RB with_IN HBV_NP in_IN vivo_JJ ,_, but_CC the_DT infection_NN is_VBZ self-limiting_NN and_CC does_VBZ not_RB lead_VB to_TO a_DT chronic_JJ carrier_NN state_NN ._SENT Furthermore_RB ,_, a_DT natural_JJ tupaia_NP hepatitis_NP B_NP virus_NN has_VBZ not_RB yet_RB been_VBN reported_VBN ._SENT Primary_JJ Tupaia_NP hepatocyte_NN cultures_NNS can_MD be_VB infected_VBN with_IN HBV_NP and_CC with_IN woolly_JJ monkey_NN hepatitis_NP B_NP virus_NN ,_, but_CC not_RB with_IN woodchuck_NN hepatitis_NN virus_NN ._SENT This_DT finding_NN confirmed_VBD the_DT susceptibility_NN of_IN primary_JJ Tupaia_NP hepatocyte_NN cultures_NNS to_TO primate_NN hepadnaviruses_NNS ,_, but_CC the_DT specificity_NN of_IN virus_NN attachment_NN and_CC entry_NN has_VBZ not_RB yet_RB been_VBN demonstrated_VBN ._SENT It_PP is_VBZ known_VBN that_IN after_IN a_DT nonspecific_JJ uptake_NN of_IN hepadnavirus_NN genomes_NNS ,_, later_JJR steps_NNS of_IN the_DT viral_JJ life_NN cycle_NN are_VBP not_RB rigidly_RB host_VB restricted_VBN ,_, as_RB is_VBZ shown_VBN by_IN transgenic_JJ HBV-producing_NN mice_NNS ._SENT The_DT orthohepadnaviruses_NNS contain_VBP three_CD coterminal_JJ surface_NN proteins_NNS (_( large_RB [_SYM LHBs_NP ]_SYM ,_, medium_NN [_SYM MHBs_NP ]_SYM ,_, and_CC small_RB [_SYM SHBs_NP ]_SYM HBs_NP )_) with_IN the_DT three_CD domains_NNS pre-S1_JJ ,_, pre-S2_JJ ,_, and_CC S._NP Attachment_NP of_IN HBV_NP to_TO human_JJ hepatocytes_NNS is_VBZ mediated_VBN by_IN the_DT pre-S1_JJ domain_NN and_CC is_VBZ blocked_VBN by_IN a_DT monoclonal_NN antibody_NN (_( MAb_NP )_) against_IN pre-S1_JJ (_( Ma18/7_JJ )_) ._SENT Furthermore_RB ,_, antibodies_NNS against_IN S_NP protect_VB against_IN infection_NN ,_, whereas_IN the_DT pre-S2_JJ domain_NN seems_VBZ to_TO be_VB nonessential_JJ for_IN attachment_NN ._SENT In_IN the_DT study_NN presented_VBD here_RB ,_, we_PP established_VBD optimized_VBN primary_JJ hepatocyte_NN cultures_NNS from_IN tupaia_NP livers_NNS and_CC developed_VBN quantitative_JJ real-time_JJ PCR_NP techniques_NNS for_IN detecting_VBG HBV_NP DNA_NP transport_NN to_TO the_DT nucleus_NN and_CC viral_JJ gene_NN expression_NN ._SENT We_PP found_VBD that_IN uptake_NN and_CC gene_NN expression_NN of_IN HBV_NP may_MD be_VB specifically_RB blocked_VBN by_IN antibodies_NNS against_IN those_DT protein_NN sequences_NNS which_WDT have_VBP been_VBN found_VBN to_TO be_VB essential_JJ for_IN infection_NN of_IN human_JJ hepatocytes_NNS ._SENT The_DT results_NNS show_VBP that_IN primary_JJ Tupaia_NP hepatocyte_NN cultures_NNS are_VBP suitable_JJ for_IN studying_VBG early_JJ steps_NNS in_IN the_DT life_NN cycle_NN of_IN HBV_NP ,_, for_IN assay_NN of_IN its_PP$ infectivity_NN ,_, and_CC for_IN assays_NNS of_IN neutralizing_VBG antibodies_NNS ._SENT HBV-containing_NP plasma_NN ._SENT |_SYM HBV_NP and_CC HBsAg_NP was_VBD isolated_VBN from_IN the_DT plasma_NN of_IN two_CD chronic_JJ HBV_NP carriers_NNS ._SENT One_CD carrier_NN (_( ID1_NP )_) had_VBD 4.3_CD x_SYM 109_CD HBV_NP genomes/ml_NN ,_, genotype_NN D_NP ,_, and_CC 100_CD mug_NN of_IN HBsAg_NP subtype_NN ayw2/ml_NN and_CC was_VBD positive_JJ for_IN HBV_NP e_SYM antigen_NN (_( HBeAg_NP )_) ._SENT The_DT second_JJ carrier_NN (_( ID259_NP )_) had_VBD 2_CD x_SYM 109_CD HBV_NP genomes/ml_NN ,_, genotype_NN D_NP ,_, and_CC 10_CD mug_NN of_IN HBsAg/ml_NP subtype_NN ayw2_NN and_CC was_VBD positive_JJ for_IN HBeAg_NP ._SENT HBV_NP antibodies_NNS ._SENT |_SYM Monoclonal_NP antibody_NN (_( MAb_NP )_) MA18/7_JJ was_VBD generated_VBN using_VBG purified_VBN HBV_NP particles_NNS for_IN immunization_NN ._SENT MA18/7_JJ detects_VBZ an_DT epitope_NN (_( DPXF_NP )_) in_IN the_DT pre-S1_JJ amino_NN acids_NNS 20_CD to_TO 23_CD (_( 31_CD to_TO 34_CD in_IN genotype_NN A_DT )_) ._SENT Other_JJ MAbs_NNS were_VBD generated_VBN by_IN immunization_NN with_IN purified_VBN HBsAg_NP particles_NNS and_CC were_VBD characterized_VBN as_IN described_VBN previously_RB ._SENT Polyvalent_JJ anti-HBs_NNS serum_NN with_IN a_DT high_JJ proportion_NN of_IN antibodies_NNS against_IN the_DT common_JJ "_`` a_DT "_`` determination_NN was_VBD generated_VBN by_IN immunization_NN as_RB follows_VBZ ._SENT A_DT sheep_NN was_VBD injected_VBN subcutaneously_RB with_IN 200_CD mug_NN of_IN highly_RB purified_VBN native_JJ HBs_NP protein_NN filaments_NNS (_( genotype_NN D_NP )_) in_IN complete_JJ Freund_NP 's_POS adjuvant_NN ._SENT Booster_NN injections_NNS with_IN 200_CD mug_NN of_IN highly_RB purified_VBN native_JJ HBs_NP protein_NN filaments_NNS of_IN different_JJ genotypes_NNS in_IN incomplete_JJ Freund_NP 's_POS adjuvant_NN were_VBD given_VBN after_IN 3_CD (_( genotype_NN A_NP )_) and_CC 6_CD (_( genotype_NN C_NP )_) weeks_NNS ._SENT After_IN 9_CD weeks_NNS ,_, a_DT mixture_NN of_IN all_DT three_CD genotypes_NNS (_( 200_CD mug_NN )_) was_VBD injected_VBN ._SENT Blood_NN was_VBD collected_VBN 10_CD days_NNS after_IN the_DT last_JJ booster_NN injection_NN (_( Eurogenetec_NP ,_, Searing_NP ,_, Belgium_NP )_) and_CC tested_VBN for_IN reactivity_NN to_TO HBsAg_NP by_IN Laurell_NP electrophoresis_NN and_CC Western_JJ blotting_VBG ._SENT Immunoglobulin_NN G_NP (_( IgG_NP )_) was_VBD purified_VBN from_IN that_DT antiserum_NN by_IN precipitation_NN with_IN 17_CD %_NN (_( wt/wt_NN )_) Na2SO4_NP ._SENT Isolation_NN and_CC purification_NN of_IN HBV_NP virions_NNS and_CC subviral_JJ particles_NNS from_IN plasma_NN of_IN HBV-infected_JJ patients_NNS ._SENT |_SYM HBV_NP and_CC subviral_JJ particles_NNS were_VBD purified_VBN as_RB follows_VBZ ._SENT Eighteen_CD milliliters_NNS of_IN human_JJ plasma_NN was_VBD ultracentrifuged_VBN through_IN a_DT discontinuous_JJ sucrose_NN density_NN gradient_NN (_( 15_CD ,_, 25_CD ,_, 35_CD ,_, 45_CD ,_, and_CC 60_CD %_NN [_SYM wt/wt_NN ]_SYM )_) in_IN TNE_NP buffer_NN (_( 20_CD mM_NP Tris-HCl_NP [_SYM pH_NN 7.4_CD ]_SYM ,_, 140_CD mM_NP NaCl_NP ,_, 1_CD mM_NP EDTA_NP )_) for_IN 15_CD h_NN at_IN 25,000_CD rpm_NN with_IN a_DT SW_NP 28.38_CD rotor_NN (_( Beckman_NP ,_, Munich_NP ,_, Germany_NP )_) ._SENT Virus-containing_JJ fractions_NNS at_IN 40_CD to_TO 45_CD %_NN sucrose_NN were_VBD identified_VBN by_IN quantitative_JJ real-time_JJ PCR_NP (_( LightCycler_NP system_NN ,_, Roche_NP ,_, Mannheim_NP ,_, Germany_NP )_) using_VBG primers_NNS and_CC hybridization_NN probes_NNS against_IN the_DT HBV_NP X_NP region_NN as_RB described_VBD previously_RB ._SENT The_DT assay_NN was_VBD calibrated_VBN using_VBG the_DT Eurohep_JJ reference_NN plasma_NN ,_, which_WDT has_VBZ been_VBN converted_VBN to_TO a_DT World_NP Health_NP Organization_NP international_JJ standard_JJ sample_NN ._SENT Sucrose_NN was_VBD removed_VBN by_IN using_VBG Vivaspin_NP 6_CD concentrators_NNS (_( Vivascience_NP ,_, Sartorius_NP ,_, Germany_NP )_) ,_, and_CC the_DT concentrated_JJ virus_NN in_IN TNE_NP buffer_NN (_( 0.2_CD ml_NN from_IN 19_CD ml_NN of_IN plasma_NN )_) was_VBD snap-frozen_VBN in_IN liquid_JJ N2_NP and_CC stored_VBN at_IN -70C_NN until_IN it_PP was_VBD used_VBN ._SENT The_DT fractions_NNS containing_VBG 35_CD to_TO 40_CD %_NN sucrose_NN were_VBD analyzed_VBN by_IN sodium_NN dodecyl_NN sulfate-polyacrylamide_NN gel_NN electrophoresis_NN and_CC silver_NN stained_VBN for_IN detection_NN of_IN HBs_NP proteins_NNS in_IN subviral_JJ HBsAg_NP particles_NNS ._SENT Fractions_NNS were_VBD pooled_VBN ,_, adjusted_VBN with_IN solid_JJ CsCl_NN to_TO 1.30_CD g/ml_NN ,_, and_CC layered_VBD within_IN a_DT CsCl_NP density_NN gradient_NN ranging_VBG from_IN 1.16_CD to_TO 1.35_CD g/ml_NN in_IN TNE_NP buffer_NN for_IN 36_CD h_NN at_IN 25,000_CD rpm_NN in_IN an_DT SW_NP 28.38_CD rotor_NN (_( Beckman_NP )_) ._SENT HBs_NNS protein-containing_VBG fractions_NNS at_IN 1.18_CD to_TO 1.22_CD g/ml_NN were_VBD dialyzed_VBN and_CC purified_VBN by_IN sedimentation_NN into_IN a_DT discontinuous_JJ sucrose_NN density_NN gradient_NN (_( 5_CD ,_, 10_CD ,_, 15_CD ,_, 20_CD ,_, 25_CD ,_, and_CC 60_CD %_NN [_SYM wt/wt_NN ]_SYM )_) in_IN TNE_NP buffer_NN for_IN 15_CD h_NN at_IN 25,000_CD rpm_NN with_IN an_DT SW_NP 28.38_CD rotor_NN ._SENT The_DT LHBs_NP protein-rich_JJ fractions_NNS containing_VBG HBsAg_NP filaments_NNS were_VBD separated_VBN from_IN the_DT HBs_NP spheres_NNS ,_, pooled_VBN ,_, and_CC concentrated_VBD in_IN a_DT Vivaspin-20_NP ultrafiltration_NN device_NN (_( Vivascience_NP )_) ._SENT The_DT concentration_NN of_IN purified_VBN HBsAg_NP was_VBD estimated_VBN from_IN the_DT optical_JJ density_NN at_IN 280_CD nm_NN (_( OD280_NP )_) ,_, assuming_VBG a_DT value_NN of_IN 4.3_CD for_IN 1_CD mg_NN of_IN HBsAg/ml_NP ._SENT The_DT purity_NN of_IN the_DT HBsAg_NP filament_NN preparation_NN was_VBD controlled_VBN by_IN gel_NN electrophoresis_NN and_CC silver_NN staining_VBG of_IN the_DT gel_NN as_RB described_VBD previously_RB ._SENT Isolation_NN and_CC culture_NN of_IN primary_JJ Tupaia_NP hepatocytes_NNS ._SENT |_SYM Tupaia_NP belangeri_NP (_( the_DT Asian_JJ tree_NN shrew_NN )_) was_VBD bred_VBN in_IN the_DT animal_JJ facility_NN of_IN the_DT Institute_NP of_IN Anatomy_NP and_CC Cell_NP Biology_NP at_IN the_DT Justus_NP Liebig_NP University_NP of_IN Giessen_NP ._SENT Primary_JJ hepatocytes_NNS were_VBD isolated_VBN by_IN the_DT modified_JJ two-step_JJ collagenase_NN method_NN first_RB described_VBN by_IN Seglen_NP ._SENT In_IN brief_NN ,_, the_DT livers_NNS of_IN 2-_CD to_TO 4-year-old_JJ tupaias_NNS (_( 8_CD to_TO 10_CD g_NN [_SYM wet_JJ weight_NN ]_SYM )_) were_VBD perfused_VBN via_IN the_DT portal_NN vein_NN with_IN Hanks_NP solution_NN (_( Invitrogen_NP ,_, Karlsruhe_NP ,_, Germany_NP )_) containing_VBG 5_CD mM_NP EGTA_NP at_IN a_DT flow_NN rate_NN of_IN 10_CD ml/min_NN for_IN 7_CD min_NN ,_, followed_VBN by_IN perfusion_NN with_IN Dulbecco_NP 's_POS modified_JJ Eagle_NP 's_POS medium_NN (_( Invitrogen_NP )_) containing_VBG 0.05_CD %_NN collagenase_NN (_( type_NN II_NP ;_: Sigma_NP ,_, Deisenhofen_NP ,_, Germany_NP )_) for_IN at_IN least_JJS 15_CD min_NN at_IN 37C_JJ ._SENT The_DT cell_NN suspension_NN was_VBD rinsed_VBN through_IN a_DT layer_NN of_IN nylon_NN filter_NN (_( pore_NN size_NN ,_, 250_CD mum_NN )_) and_CC thereafter_RB through_IN a_DT 75-mum-pore-size_JJ nylon_NN filter_NN ,_, yielding_VBG isolated_VBN single_JJ or_CC double_JJ hepatocytes_NNS ._SENT After_IN the_DT hepatocytes_NNS were_VBD pelleted_VBN three_CD times_NNS at_IN 30_CD x_NN g_NN for_IN 5_CD min_NN at_IN 4C_NP ,_, the_DT cells_NNS were_VBD resuspended_VBN in_IN plating_VBG medium_NN (_( Williams_NP E_NP medium_NN [_SYM Invitrogen_NP ]_SYM supplemented_VBN with_IN 5_CD mug_NN of_IN insulin/ml_NN ,_, 5_CD mug_NN of_IN transferrin/ml_NN ,_, 5_CD ng_NNS of_IN sodium_NN selenite/ml_NN ,_, 100_CD mug_NN of_IN gentamicin/ml_NN ,_, and_CC 0.25_CD mug_NN of_IN amphotericin_NP B/ml_NP with_IN 5_CD %_NN fetal_JJ calf_NN serum_NN )_) and_CC poured_VBN on_IN collagen-coated_JJ coverslips_NNS (_( collagen_NN I_PP from_IN rat_NN tail_NN ;_: BD_NP Bioscience_NP ,_, Heidelberg_NP ,_, Germany_NP )_) in_IN 24-well_JJ plates_NNS (_( 103_CD hepatocytes_NNS per_IN well_RB )_) or_CC on_IN collagen-coated_JJ cell_NN culture_NN dishes_NNS (_( 105_CD hepatocytes_NNS per_IN 3-cm-diameter_JJ dish_NN )_) ._SENT After_IN 2_CD to_TO 4_CD h_NN at_IN 37C_NP ,_, the_DT plating_VBG medium_NN with_IN unattached_JJ cells_NNS was_VBD removed_VBN and_CC the_DT cells_NNS were_VBD incubated_VBN with_IN maintenance_NN medium_NN (_( Williams_NP E_NP medium_NN supplemented_VBD with_IN 0.1_CD %_NN bovine_JJ serum_NN albumin_NN [_SYM crystallized_VBN ;_: Sigma_NP ]_SYM ,_, 5_CD mug_NN of_IN insulin/ml_NN ,_, 5_CD mug_NN of_IN transferrin/ml_NN ,_, 5_CD ng_NNS of_IN sodium_NN selenite/ml_NN ,_, 50_CD muM_NN hydrocortisone_NN ,_, 0.1_CD muM_NN dexamethasone_NN ,_, 2_CD %_NN dimethyl_NN sulfoxide_NN ,_, 100_CD mug_NN of_IN gentamicin/ml_NN ,_, and_CC 0.25_CD mug_NN of_IN amphotericin_NP B/ml_NP )_) until_IN infection_NN ._SENT Infection_NN of_IN primary_JJ Tupaia_NP hepatocyte_NN cultures_NNS ._SENT |_SYM Primary_NP Tupaia_NP hepatocyte_NN cultures_NNS were_VBD inoculated_VBN 3_CD days_NNS after_IN being_VBG plated_VBN with_IN purified_VBN virus_NN at_IN appropriate_JJ concentrations_NNS in_IN infection_NN medium_NN (_( Williams_NP E_NP medium_NN supplemented_VBD with_IN 0.1_CD %_NN bovine_JJ serum_NN albumin_NN [_SYM crystallized_VBN ;_: Sigma_NP ]_SYM ,_, 2_CD %_NN dimethyl_NN sulfoxide_NN ,_, 100_CD mug_NN of_IN gentamicin/ml_NN ,_, and_CC 0.25_CD mug_NN of_IN amphotericin_NP B/ml_NP )_) for_IN 12_CD h_NN at_IN 37C_JJ ._SENT The_DT cells_NNS were_VBD extensively_RB washed_VBN with_IN infection_NN medium_NN and_CC further_RBR cultivated_VBN in_IN maintenance_NN medium_NN ._SENT The_DT medium_NN was_VBD changed_VBN every_DT 3_CD days_NNS and_CC measured_VBN for_IN the_DT appearance_NN of_IN secreted_VBN HBV_NP antigens_NNS ._SENT After_IN 12_CD days_NNS ,_, the_DT cells_NNS were_VBD washed_VBN with_IN phosphate-buffered_JJ saline_NN (_( PBS_NP )_) and_CC lysed_VBN with_IN lysis_NN buffer_NN (_( 100_CD mM_NP NaCl_NP ,_, 50_CD mM_NP Tris_NP ,_, 0.1_CD %_NN Triton_NP X-100_NP ,_, 5_CD mM_NP MgCl2_NP ,_, pH_NN 8.0_CD )_) for_IN 10_CD min_NN at_IN 4C_JJ ._SENT Nuclei_NNS were_VBD separated_VBN from_IN the_DT cytoplasmic_JJ fraction_NN by_IN centrifugation_NN at_IN 270_CD x_NN g_NN for_IN 2_CD min_NN at_IN 4C_JJ ._SENT The_DT cytosolic_JJ and_CC nucleic_JJ fractions_NNS were_VBD snap-frozen_VBN in_IN liquid_JJ nitrogen_NN and_CC stored_VBD at_IN -70C_NN until_IN they_PP were_VBD used_VBN ._SENT Assay_NN for_IN HBV-specific_JJ proteins_NNS ._SENT |_SYM HBeAg_NP was_VBD determined_VBN semiquantitatively_RB by_IN a_DT commercially_RB available_JJ enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) (_( AxSym_NP ;_: Abbott_NP Laboratories_NPS ,_, Weisbaden_NP ,_, Germany_NP )_) ._SENT HBs_NNS was_VBD measured_VBN by_IN an_DT in-house_JJ sandwich_NN ELISA_NP as_RB described_VBD previously_RB ._SENT In_IN brief_NN ,_, 96-well_NN plates_NNS (_( Maxi-Sorb_NP ;_: Nunc_NP ,_, Hereford_NP ,_, United_NP Kingdom_NP )_) were_VBD coated_VBN with_IN 1_CD mug_NN of_IN MAb_NP C20/2_NP per_IN ml_NN against_IN HBsAg_NP a_DT determinant_NN in_IN PBS_NP for_IN 2_CD h_NN at_IN 37C_JJ ._SENT After_IN being_VBG extensively_RB washed_JJ (_( three_CD times_NNS with_IN PBS-0.1_JJ %_NN Tween_NP 20_CD and_CC two_CD times_NNS with_IN PBS_NP )_) and_CC subsequently_RB blocked_VBN with_IN 10_CD %_NN fetal_JJ calf_NN serum_NN in_IN PBS_NP for_IN 1_CD h_NN at_IN 37C_JJ ,_, 100_CD mul_NN of_IN undiluted_JJ cell_NN culture_NN supernatant_JJ from_IN infected_JJ hepatocyte_NN cultures_NNS was_VBD incubated_VBN for_IN 12_CD h_NN at_IN 4C_JJ ._SENT After_IN removal_NN of_IN the_DT supernatant_JJ ,_, the_DT plate_NN was_VBD again_RB washed_VBN with_IN PBS_NP and_CC PBS-0.1_NP %_NN Tween_NP 20_CD ,_, and_CC peroxidase-conjugated_JJ anti-HBs_NNS from_IN the_DT Enzygnost_NP HBsAg_NP ELISA_NP kit_NN (_( Dade_NP Behring_NP ,_, Marburg_NP ,_, Germany_NP )_) was_VBD added_VBN to_TO each_DT well_RB and_CC incubated_VBN for_IN 1_CD h_NN at_IN 37C_JJ ._SENT After_IN the_DT plate_NN was_VBD washed_VBN as_IN described_VBN above_IN ,_, an_DT o-phenylenediamine-H2O2_JJ substrate_NN (_( tablets_NNS from_IN Abbott_NP Laboratories_NPS )_) was_VBD added_VBN for_IN 15_CD min_NN at_IN room_NN temperature_NN ,_, and_CC the_DT amount_NN of_IN colored_JJ product_NN was_VBD determined_VBN by_IN measuring_VBG the_DT OD492_NP ._SENT The_DT concentration_NN of_IN HBsAg_NP was_VBD calculated_VBN in_IN comparison_NN to_TO a_DT dilution_NN series_NN of_IN a_DT well-defined_JJ HBV_NP plasma_NN containing_VBG 100_CD to_TO 0.01_CD ng_NNS of_IN HBsAg_NP ,_, according_VBG to_TO previous_JJ calibrations_NNS ._SENT Quantification_NN of_IN HBV_NP cccDNA_NN in_IN HBV-infected_JJ cells_NNS ._SENT |_SYM Episomal_NP DNA_NP was_VBD isolated_VBN from_IN nuclei_NNS of_IN infected_JJ Tupaia_NP hepatocytes_NNS by_IN Hirt_NP extraction_NN as_RB described_VBD previously_RB ._SENT Eluted_VBN HBV_NP DNA_NP was_VBD further_RBR purified_VBN using_VBG a_DT DNA_NP extraction_NN kit_NN (_( Highpure_NP ;_: Roche_NP )_) ._SENT The_DT purified_VBN DNA_NN was_VBD used_VBN for_IN PCR_NP (_( LightCycler_NP real-time_JJ system_NN with_IN Fast_NP Start_NP PCR_NP kit_NN ;_: Roche_NP )_) with_IN the_DT primer_NN set_VBD HBV_NP C1_NP sense_NN (_( nucleotides_NNS 1580_CD to_TO 1596_CD ;_: 5'TGCACTTCGCTTCACCT_NP )_) and_CC HBV_NP C1_NP antisense_NN (_( nucleotides_NNS 2314_CD to_TO 2298_CD ;_: 5'AGGGGCATTTGGTGGTC_NP )_) for_IN detection_NN of_IN HBV_NP DNA_NP without_IN nick_NN and_CC gap_NN (_( covalently_RB closed_VBN circular_JJ DNA_NN [_SYM cccDNA_NN ]_SYM )_) under_IN the_DT following_VBG conditions_NNS :_: denaturation_NN (_( 1_CD time_NN )_) ,_, 95C_NN for_IN 10_CD min_NN ;_: amplification_NN (_( 45_CD times_NNS )_) ,_, 95C_NN for_IN 10_CD s_NNS ,_, 57C_NN for_IN 20_CD s_NNS ,_, and_CC 72C_NP for_IN 32_CD s_NNS ;_: slope_NN of_IN temperature_NN changes_NNS ,_, 20C/s_JJ ._SENT The_DT resulting_VBG amplificate_NN (_( 735_CD bp_NN )_) was_VBD subjected_VBN to_TO 2_CD %_NN agarose_NN gel_NN electrophoresis_NN and_CC visualized_VBN by_IN ethidium_NN bromide_NN staining_VBG ._SENT Purification_NN of_IN poly(A)+_NP RNA_NP and_CC quantitative_JJ one-tube_NN HBV_NP RT-PCR_NP ._SENT |_SYM Poly(A)+_NP RNA_NP from_IN cytoplasmic_JJ fractions_NNS of_IN infected_JJ cells_NNS was_VBD isolated_VBN by_IN using_VBG oligo(dT)-coated_JJ paramagnetic_JJ beads_NNS (_( Dynal_NP ,_, Oslo_NP ,_, Norway_NP )_) according_VBG to_TO the_DT manufacturer_NN 's_POS guidelines_NNS ._SENT The_DT HBV_NP mRNA_NN in_IN this_DT extract_NN was_VBD quantified_VBN using_VBG the_DT one-tube_NN real-time_JJ reverse_JJ transcription_NN (RT)-PCR_NN kit_NN for_IN LightCycler_NP (_( Roche_NP )_) according_VBG to_TO the_DT manufacturer_NN 's_POS guidelines_NNS with_IN primers_NNS and_CC hybridization_NN probes_NNS for_IN the_DT X_NP region_NN as_RB described_VBD previously_RB ._SENT For_IN generation_NN of_IN a_DT reference_NN sample_NN HBV_NP RNA_NP ,_, the_DT X_NP region_NN was_VBD transcribed_VBN from_IN plasmid_NP pCX_NN using_VBG the_DT T7_JJ in_IN vitro_NN transcription_NN kit_NN (_( Roche_NP )_) according_VBG to_TO the_DT manufacturer_NN 's_POS guidelines_NNS ._SENT The_DT resulting_VBG RNA_NP was_VBD incubated_VBN with_IN 10_CD U_NN of_IN RNase-free_NP DNase_NP I_NP (Roche)/mul_NN for_IN 1_CD h_NN at_IN 37C_JJ and_CC further_RBR purified_VBD by_IN phenol-chloroform_NN extraction_NN ._SENT The_DT RNA_NP copy_NN number_NN was_VBD determined_VBN by_IN measuring_VBG the_DT OD260_NP ._SENT The_DT HBV_NP RNA_NP served_VBD as_IN a_DT standard_NN in_IN quantitative_JJ HBV_NP RT-PCR_NP using_VBG serial_JJ dilutions_NNS ._SENT Binding_JJ and_CC uptake_NN studies_NNS ._SENT |_SYM Primary_NP Tupaia_NP hepatocytes_NNS (_( 1_CD x_SYM 103_CD to_TO 5_CD x_SYM 103_CD )_) were_VBD plated_VBN on_IN collagen-coated_JJ glass_NN coverslips_NNS in_IN plating_VBG medium_NN as_RB described_VBD above_IN ._SENT After_IN 2_CD to_TO 4_CD h_NN at_IN 37C_NP ,_, the_DT plating_VBG medium_NN with_IN unattached_JJ cells_NNS was_VBD removed_VBN and_CC the_DT cells_NNS were_VBD further_RBR incubated_VBN with_IN maintenance_NN medium_NN until_IN they_PP were_VBD used_VBN ._SENT For_IN binding_JJ experiments_NNS ,_, cells_NNS were_VBD washed_VBN twice_RB with_IN Williams_NP E_NP medium_NN and_CC once_RB with_IN binding_JJ medium_NN (_( Williams_NP E_NP medium_NN supplemented_VBD with_IN 0.1_CD %_NN crystallized_VBD bovine_JJ serum_NN albumin_NN sigma_NN )_) ._SENT Purified_VBN pre-S1-rich_JJ HBs_NP filaments_NNS were_VBD diluted_VBN in_IN binding_JJ medium_NN to_TO yield_VB a_DT final_JJ concentration_NN of_IN 2_CD mug/ml_NN ._SENT For_IN inhibition_NN of_IN binding_NN ,_, the_DT subviral_JJ particles_NNS were_VBD preincubated_VBN with_IN an_DT excess_NN of_IN purified_VBN polyvalent_JJ anti-HBs_NP IgG_NP (_( from_IN sheep_NN )_) for_IN 1_CD h_NN at_IN 37C_JJ ._SENT The_DT cells_NNS were_VBD incubated_VBN for_IN various_JJ times_NNS at_IN various_JJ temperatures_NNS and_CC were_VBD washed_VBN several_JJ times_NNS with_IN ice-cold_JJ Williams_NP E_NN medium_NN ._SENT The_DT cells_NNS were_VBD fixed_VBN with_IN 4_CD %_NN paraformaldehyde_NN for_IN 30_CD min_NN at_IN 4C_JJ and_CC permeabilized_VBN with_IN 0.1_CD %_NN Triton_NP X-100_NP in_IN PBS_NP for_IN 30_CD min_NN at_IN room_NN temperature_NN ._SENT HBsAg_NN staining_VBG was_VBD done_VBN with_IN the_DT APAAP_NN staining_VBG kit_NN (_( DAKO_NP ,_, Hamburg_NP ,_, Germany_NP )_) according_VBG to_TO the_DT manufacturer_NN 's_POS guidelines_NNS using_VBG an_DT anti-HBs_NNS specific_JJ MAb_NP at_IN 1:400_CD dilution_NN (_( Novocastra_NP ,_, Newcastle_NP ,_, United_NP Kingdom_NP )_) ._SENT The_DT slides_NNS were_VBD counterstained_VBN with_IN Meyer_NP 's_POS hemalaun_NN (_( Merck_NP )_) and_CC mounted_VBN in_IN Glycergel_NP (_( DAKO_NP )_) ._SENT Isolation_NN and_CC cultivation_NN of_IN primary_JJ Tupaia_NP hepatocytes_NNS ._SENT |_SYM The_DT two-step_JJ collagenase_NN perfusion_NN of_IN tupaia_NP livers_NNS routinely_RB yielded_VBD pure_JJ hepatocyte_NN cultures_NNS with_IN a_DT viability_NN of_IN >98_JJ %_NN hepatocytes_NNS (_( in_IN the_DT trypan_JJ blue_JJ assay_NN )_) and_CC <1%_contamination 1_CD month_NN in_IN a_DT highly_RB differentiated_VBN state_NN ._SENT Infection_NN of_IN primary_JJ Tupaia_NP hepatocytes_NNS with_IN purified_VBN HBV_NP ._SENT |_SYM None_NN of_IN the_DT previously_RB known_VBN cell_NN culture_NN systems_NNS for_IN hepadnaviruses_NNS produces_VBZ more_JJR output_NN than_IN input_NN virus_NN ,_, and_CC a_DT cytopathic_JJ effect_NN has_VBZ never_RB been_VBN detectable_JJ ._SENT Instead_RB ,_, "_`` infectivity_NN "_'' is_VBZ considered_VBN the_DT ability_NN of_IN hepadnaviruses_NNS to_TO specifically_RB enter_VB cells_NNS and_CC have_VB their_PP$ nicked_VBN and_CC gapped_VBN DNA_NN transported_VBN into_IN the_DT nucleus_NN ,_, where_WRB it_PP is_VBZ converted_VBN into_IN cccDNA_NN ._SENT The_DT formation_NN of_IN cccDNA_NN is_VBZ a_DT prerequisite_NN for_IN entering_VBG the_DT replication_NN cycle_NN of_IN HBV_NP and_CC is_VBZ generally_RB considered_VBN to_TO be_VB the_DT earliest_JJS marker_NN of_IN HBV_NP infection_NN of_IN the_DT hepatocyte_NN ._SENT To_TO detect_VB the_DT very_RB low_JJ cccDNA_NN content_NN in_IN infected_JJ hepatocytes_NNS ,_, we_PP used_VBD a_DT special_JJ PCR_NP protocol_NN that_WDT discriminates_VBZ specifically_RB between_IN the_DT nick-and-gap-containing_JJ HBV_NP genome_NN of_IN the_DT infecting_VBG virus_NN and_CC the_DT cccDNA_NN in_IN the_DT nucleus_NN ._SENT Reliable_JJ discrimination_NN between_IN cccDNA_NN and_CC relaxed_VBD circular_JJ DNA_NN (_( rcDNA_NN )_) is_VBZ only_RB possible_JJ when_WRB a_DT special_JJ temperature_NN protocol_NN is_VBZ used_VBN for_IN PCR_NP in_IN quartz_NN capillaries_NNS with_IN very_RB rapid_JJ temperature_NN changes_NNS (_( Fig._NN ,_, left_JJ )_) ._SENT This_DT PCR_NP detects_VBZ 1,000_CD copies_NNS of_IN cloned_VBN dimeric_JJ HBV_NP DNA_NP within_IN a_DT plasmid_NN but_CC not_RB 105_CD genome_NN equivalents_NNS (_( ge_NN )_) of_IN HBV_NP DNA_NP from_IN human_JJ plasma-derived_JJ virions_NNS (_( Fig._NN ,_, right_JJ )_) ._SENT For_IN infection_NN experiments_NNS ,_, we_PP usually_RB incubated_VBD 2_CD x_NN 105_CD to_TO 5_CD x_SYM 105_CD primary_JJ Tupaia_NP hepatocytes_NNS in_IN 3-cm-diameter_JJ dishes_NNS with_IN defined_VBN numbers_NNS of_IN purified_VBN plasma-derived_JJ HBV_NP particles_NNS determined_VBN as_IN HBV_NP ge_NNS ._SENT To_TO determine_VB the_DT minimal_JJ amount_NN of_IN purified_VBN HBV_NP necessary_JJ to_TO detect_VB infection_NN in_IN our_PP$ system_NN ,_, we_PP titrated_VBD the_DT input_NN virus_NN ;_: 105_CD hepatocytes_NNS were_VBD infected_VBN with_IN ratios_NNS of_IN 1,000_CD ,_, 100_CD ,_, 10_CD ,_, 1_CD ,_, and_CC 0.1_CD ge/hepatocyte_NN and_CC were_VBD subsequently_RB cultivated_VBN as_IN described_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT Using_VBG cccDNA-specific_JJ PCR_NP ,_, after_IN 12_CD days_NNS we_PP could_MD detect_VB HBV_NP DNA_NP without_IN nick_NN and_CC gap_NN in_IN nuclear_JJ extracts_VBZ of_IN cultures_NNS incubated_VBN with_IN HBV_NP input_NN virus_NN down_RB to_TO a_DT ratio_NN of_IN 10_CD ge/hepatocyte_NN ._SENT When_WRB the_DT viral_JJ input_NN was_VBD increased_VBN from_IN 10_CD to_TO 100_CD ge/hepatocyte_NN ,_, the_DT amount_NN of_IN cccDNA_NN also_RB increased_VBD (_( Fig._NN ,_, center_NN )_) ._SENT Further_RBR increasing_VBG the_DT viral_JJ input_NN (_( to_TO 1,000_CD ge/hepatocyte_NN )_) increased_VBD the_DT cccDNA_NN content_NN only_RB marginally_RB ._SENT The_DT HBV_NP mRNA_NN in_IN the_DT cytosolic_JJ fraction_NN was_VBD isolated_VBN on_IN day_NN 12_CD postinfection_NN (_( p.i._JJ )_) by_IN oligo(dT)_JJ purification_NN and_CC determined_VBN by_IN real-time_JJ RT-PCR_NP (_( with_IN primers_NNS from_IN the_DT X_NP region_NN )_) as_IN described_VBN above_IN ._SENT Due_JJ to_TO the_DT relatively_RB large_JJ abundance_NN of_IN HBV_NP mRNA_NP in_IN the_DT cytoplasm_NN of_IN the_DT same_JJ cells_NNS on_IN day_NN 12_CD p.i._NN ,_, a_DT 1-ge/hepatocyte_JJ ratio_NN of_IN input_NN virus_NN was_VBD sufficient_JJ to_TO detect_VB an_DT HBV_NP infection_NN in_IN primary_JJ Tupaia_NP hepatocyte_NN cultures_NNS ._SENT The_DT amount_NN of_IN cytosolic_JJ HBV_NP mRNA_NN increased_VBD proportionally_RB with_IN increased_VBN HBV_NP input_NN ._SENT Kinetics_NNS of_IN infection_NN ._SENT |_SYM By_IN changing_VBG the_DT culture_NN medium_NN every_DT 3_CD days_NNS ,_, we_PP determined_VBD the_DT onset_NN of_IN HBsAg_NP and_CC HBeAg_NP production_NN after_IN infection_NN ._SENT The_DT soluble_JJ HBeAg_NP is_VBZ not_RB associated_VBN with_IN virus_NN and_CC is_VBZ therefore_RB not_RB present_JJ in_IN the_DT purified_VBN input_NN virus_NN ._SENT Thus_RB ,_, HBeAg_NP is_VBZ a_DT marker_NN for_IN de_NP novo_NP HBV_NP protein_NN expression_NN ._SENT With_IN a_DT ratio_NN of_IN 100_CD HBV_NP ge/hepatocyte_NN ,_, newly_RB synthesized_VBD HBeAg_NP could_MD be_VB detected_VBN after_IN 6_CD days_NNS and_CC reached_VBD a_DT plateau_NN at_IN day_NN 9_CD to_TO day_NN 12_CD ._SENT Increasing_VBG the_DT viral_JJ input_NN to_TO 1,000_CD HBV_NP ge/hepatocyte_NN did_VBD not_RB lead_VB to_TO increased_VBN HBeAg_NP secretion_NN on_IN day_NN 12_CD (_( data_NNS not_RB shown_VBN )_) ,_, while_IN reducing_VBG the_DT input_NN from_IN 100_CD to_TO 10_CD HBV_NP ge/hepatocyte_NN also_RB decreased_VBD the_DT HBeAg_NP output_NN 10-fold_NN ,_, and_CC HBeAg_NP production_NN could_MD first_RB be_VB detected_VBN only_RB on_IN day_NN 9_CD ._SENT At_IN 1_CD ge/hepatocyte_NN or_CC below_RB ,_, no_DT significant_JJ ELISA_NP signal_NN for_IN HBeAg_NP could_MD be_VB detected_VBN ._SENT HBsAg_NP production_NN followed_VBD a_DT pattern_NN similar_JJ to_TO that_DT of_IN HBeAg_NP production_NN ._SENT Although_IN present_NN in_IN the_DT input_NN ,_, HBsAg_NP could_MD not_RB be_VB detected_VBN on_IN day_NN 3_CD ._SENT This_DT excluded_VBD the_DT possibility_NN that_IN nonspecific_JJ binding_NN to_TO the_DT cells_NNS and_CC subsequent_JJ release_NN of_IN virions_NNS into_IN the_DT medium_NN without_IN de_NP novo_NP synthesis_NN would_MD generate_VB an_DT HBsAg_NP signal_NN ._SENT With_IN a_DT ratio_NN of_IN 100_CD HBV_NP ge/hepatocyte_NN ,_, newly_RB synthesized_VBD HBsAg_NP could_MD be_VB detected_VBN 6_CD days_NNS p.i._JJ and_CC reached_VBN a_DT plateau_NN at_IN day_NN 9_CD to_TO day_NN 12_CD ._SENT As_IN detected_VBN for_IN HBeAg_NP ,_, a_DT further_JJR increase_NN of_IN the_DT input_NN to_TO 1,000_CD HBV_NP ge/hepatocyte_NN did_VBD not_RB lead_VB to_TO increased_VBN HBsAg_NP secretion_NN (_( data_NNS not_RB shown_VBN )_) ,_, while_IN reducing_VBG the_DT input_NN from_IN 100_CD to_TO 10_CD HBV_NP ge/hepatocyte_NN also_RB decreased_VBD the_DT HBsAg_NP output_NN 10-fold_NN ,_, with_IN HBsAg_NP secretion_NN first_RB detectable_JJ on_IN day_NN 9_CD ._SENT A_DT virus_NN titer_NN of_IN 1_CD ge/hepatocyte_NN still_RB led_VBN to_TO detectable_JJ production_NN of_IN HBsAg_NP on_IN day_NN 12_CD ._SENT A_DT viral_JJ inoculum_NN of_IN 0.1_CD ge/hepatocyte_NN never_RB generated_VBD a_DT detectable_JJ HBsAg_NP or_CC HBeAg_NP signal_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Thus_RB ,_, 1_CD HBV_NP ge/hepatocyte_NN is_VBZ necessary_JJ to_TO establish_VB a_DT detectable_JJ HBV_NP infection_NN in_IN the_DT type_NN of_IN primary_JJ Tupaia_NP hepatocyte_NN culture_NN used_VBN in_IN this_DT study_NN ,_, while_IN 100_CD ge/hepatocyte_NN led_VBN to_TO maximal_JJ HBsAg_NP and_CC HBeAg_NP secretion_NN ._SENT Assay_NN of_IN neutralizing_VBG antibodies_NNS against_IN HBV_NP ._SENT |_SYM To_TO determine_VB whether_IN the_DT uptake_NN of_IN HBV_NP by_IN primary_JJ Tupaia_NP hepatocytes_NNS required_VBD specific_JJ attachment_NN sites_NNS on_IN HBV_NP ,_, we_PP preincubated_VBD the_DT virus_NN with_IN various_JJ antibodies_NNS against_IN HBV_NP surface_NN proteins_NNS ._SENT We_PP used_VBD a_DT large_JJ stoichiometric_JJ excess_NN (_( >10-fold_NN )_) of_IN different_JJ MAbs_NNS directed_VBN against_IN the_DT pre-S1_JJ ,_, pre-S2_JJ ,_, or_CC S_NP domain_NN of_IN HBV_NP surface_NN proteins_NNS ._SENT Preincubation_NN of_IN virus_NN with_IN MAb_NP MA18/7_NP ,_, which_WDT binds_VBZ to_TO amino_NN acids_NNS 20_CD to_TO 23_CD of_IN the_DT pre-S1_JJ domain_NN (_( DPAF_NP )_) ,_, completely_RB prevented_VBN infection_NN ,_, because_IN HBeAg_NP and_CC HBsAg_NP production_NN were_VBD not_RB detectable_JJ in_IN culture_NN supernatants_NNS as_IN they_PP were_VBD in_IN control_NN infections_NNS ._SENT Analysis_NN of_IN HBV_NP cccDNA_NN content_NN and_CC HBV_NP mRNA_NP in_IN these_DT cells_NNS on_IN day_NN 12_CD p.i._NN confirmed_VBD that_DT preincubation_NN with_IN MAb_NP MA18/7_NP also_RB prevented_VBD the_DT formation_NN of_IN cccDNA_NP and_CC HBV_NP mRNA_NP ._SENT Complete_JJ inhibition_NN of_IN infection_NN could_MD also_RB be_VB achieved_VBN by_IN preincubation_NN with_IN polyclonal_JJ anti-HBs_NNS antibodies_NNS produced_VBN in_IN sheep_NN against_IN purified_VBN plasma-derived_JJ HBsAg_NN of_IN different_JJ HBV_NP genotypes_NNS (_( Fig._NN and_CC C_NP )_) ._SENT Among_IN the_DT two_CD MAbs_NNS directed_VBN against_IN the_DT S_NP domain_NN ,_, only_RB MAb_NP C20/2_NP ,_, which_WDT recognizes_VBZ a_DT conformational_JJ epitope_NN ,_, was_VBD also_RB capable_JJ of_IN inhibiting_VBG infection_NN ,_, as_RB shown_VBN by_IN negative_JJ results_NNS for_IN HBeAg_NP and_CC HBsAg_NP (_( Fig._NN and_CC C_NP )_) and_CC HBV_NP cccDNA_NN and_CC mRNA_NN ._SENT MAb_NP 1-9C1_NP ,_, which_WDT binds_VBZ to_TO a_DT linear_JJ genotype_NN D-specific_NP S_NP epitope_NN ,_, was_VBD not_RB able_JJ to_TO completely_RB inhibit_VB infection_NN (_( Fig._NN and_CC C_NP )_) ._SENT MAbs_NNS against_IN the_DT pre-S2_JJ domain_NN showed_VBD variable_JJ neutralization_NN capacity_NN ._SENT MAb_JJ 2-12F2_JJ (_( an_DT IgM_NP antibody_NN )_) did_VBD not_RB inhibit_VB infection_NN efficiently_RB ,_, since_IN we_PP could_MD clearly_RB detect_VB HBV_NP cccDNA_NN 12_CD days_NNS p.i._JJ The_DT HBV_NP mRNA_NN signal_NN was_VBD only_RB 74_CD %_NN less_JJR than_IN in_IN the_DT control_NN infection_NN ._SENT HBeAg_NP and_CC HBsAg_NP secretion_NN were_VBD also_RB reduced_VBN by_IN 74_CD and_CC 82_CD %_NN ,_, respectively_RB ._SENT The_DT other_JJ IgG_NP pre-S2_NN MAbs_NNS neutralized_VBN more_RBR efficiently_RB but_CC were_VBD not_RB able_JJ to_TO inhibit_VB infection_NN completely_RB ._SENT MAbs_NNS recognizing_VBG the_DT amino-terminal_JJ region_NN of_IN the_DT pre-S2_JJ domain_NN (_( residues_NNS 5_CD to_TO 17_CD )_) showed_VBD from_IN 96_CD to_TO 99_CD %_NN inhibition_NN of_IN HBsAg_NP secretion_NN (_( MAbs_NP S26_NP and_CC 2-11B1_JJ )_) ,_, except_IN for_IN MAb_NP Q19/10_NP ,_, which_WDT preferentially_RB binds_VBZ to_TO the_DT N-glycosylated_JJ pre-S2_JJ domain_NN of_IN MHBs_NP ._SENT In_IN the_DT case_NN of_IN MAb_NP S26_NP ,_, the_DT cccDNA_NN contents_NNS in_IN the_DT nuclei_NNS of_IN infected_JJ cells_NNS dropped_VBD below_IN the_DT detection_NN limit_NN ,_, but_CC an_DT HBV_NP mRNA_NN signal_NN was_VBD still_RB detectable_JJ and_CC was_VBD reduced_VBN only_JJ 10-fold_NN ,_, indicating_VBG active_JJ replication_NN of_IN HBV_NP ._SENT Binding_JJ and_CC uptake_NN of_IN HBsAg_NP ._SENT |_SYM To_TO study_VB the_DT binding_NN and_CC uptake_NN of_IN HBV_NP by_IN primary_JJ Tupaia_NP hepatocytes_NNS ,_, we_PP used_VBD highly_RB purified_VBN pre-S1-containing_VBG HBsAg_NP filament-rich_JJ particles_NNS from_IN the_DT same_JJ patients_NNS '_POS plasmas_NNS from_IN which_WDT we_PP isolated_VBD viral_JJ fractions_NNS for_IN infection_NN experiments_NNS ._SENT After_IN incubating_VBG cell_NN cultures_NNS with_IN HBsAg_NP for_IN 1_CD h_NN at_IN 37C_JJ ,_, followed_VBN by_IN several_JJ washes_VBZ ,_, >70_JJ %_NN of_IN the_DT hepatocytes_NNS had_VBD retained_VBN HBsAg_NP and_CC reacted_VBD with_IN an_DT HBsAg-specific_JJ immune_JJ stain_NN ._SENT This_DT effect_NN could_MD be_VB completely_RB abrogated_VBN by_IN preincubating_VBG HBsAg_NP with_IN a_DT polyclonal_JJ anti-HBs_NNS antibody_NN ._SENT Interestingly_RB ,_, HBsAg_NP was_VBD not_RB evenly_RB distributed_VBN on_IN the_DT membranes_NNS of_IN hepatocytes_NNS but_CC appeared_VBD to_TO be_VB located_VBN in_IN distinct_JJ areas_NNS of_IN the_DT cell_NN surface_NN (_( Fig._NN and_CC C_NP )_) ._SENT These_DT structures_NNS ,_, most_RBS likely_JJ actin_NN bundles_NNS containing_VBG filopodia_NNS or_CC microvilli_NNS ,_, seem_VBP to_TO contain_VB large_JJ concentrations_NNS of_IN HBV_NP receptors_NNS ._SENT Some_DT hepatocytes_NNS with_IN no_DT visible_JJ signs_NNS of_IN filopodia_NNS or_CC microvilli_NNS did_VBD not_RB show_VB HBsAg_NP on_IN the_DT cell_NN surface_NN but_CC rather_RB a_DT perinuclear_JJ accumulation_NN of_IN HBsAg_NP ._SENT This_DT pattern_NN may_MD represent_VB active_JJ transport_NN from_IN the_DT plasma_NN membrane_NN to_TO cellular_JJ subcompartments_NNS ._SENT After_IN uptake_NN and_CC further_JJR cultivation_NN for_IN 2_CD h_NN ,_, the_DT signal_NN disappears_VBZ (_( data_NNS not_RB shown_VBN )_) ._SENT A_DT similar_JJ pattern_NN has_VBZ been_VBN observed_VBN using_VBG primary_JJ human_JJ hepatocytes_NNS ._SENT HBsAg_NN synthesis_NN in_IN infected_JJ hepatocytes_NNS ._SENT |_SYM For_IN detection_NN of_IN de_NP novo_NP HBsAg_NP in_IN infected_JJ hepatocytes_NNS ,_, we_PP infected_VBD primary_JJ Tupaia_NP hepatocytes_NNS with_IN 100_CD ge/hepatocyte_NN on_IN collagen-coated_JJ coverslips_NNS ._SENT After_IN 12_CD days_NNS ,_, most_JJS cells_NNS were_VBD clearly_RB HBsAg-negative_JJ ,_, but_CC up_RB to_TO 5_CD %_NN of_IN the_DT hepatocytes_NNS showed_VBD strong_JJ cytoplasmic_JJ staining_VBG for_IN HBsAg_NP ._SENT Maximum_JJ infectivity_NN (_( 20_CD %_NN of_IN cells_NNS clearly_RB HBsAg_NP positive_NN )_) was_VBD achieved_VBN by_IN increasing_VBG the_DT viral_JJ input_NN to_TO 10,000_CD HBV_NP ge/cell_NNS ._SENT This_DT effect_NN could_MD be_VB inhibited_VBN completely_RB by_IN preincubating_VBG the_DT input_NN virus_NN with_IN polyclonal_JJ anti-HBs_NNS antibody_NN ._SENT The_DT majority_NN of_IN infected_JJ cells_NNS showed_VBD clear_JJ cytoplasmic_JJ and_CC occasionally_RB very_RB strong_JJ perinuclear_NN staining_VBG (_( Fig._NN and_CC D_NP )_) ,_, while_IN a_DT small_JJ population_NN of_IN cells_NNS showed_VBD only_RB marginal_JJ staining_VBG for_IN HBsAg_NP expression_NN ,_, even_RB at_IN the_DT highest_JJS viral_JJ input_NN ._SENT The_DT localized_JJ staining_VBG most_RBS likely_RB reflects_VBZ HBsAg_NP associated_VBN with_IN the_DT endoplasmic_JJ reticulum_NN ._SENT A_DT similar_JJ pattern_NN of_IN HBsAg_NP expression_NN has_VBZ also_RB been_VBN detected_VBN using_VBG a_DT human_JJ hepatoma_NN cell_NN line_NN (_( HepG2_NP )_) transfected_VBD with_IN HBV_NP DNA_NP (_( data_NN not_RB shown_VBN )_) ._SENT In_IN this_DT study_NN ,_, primary_JJ Tupaia_NP hepatocyte_NN cultures_NNS were_VBD infected_VBN with_IN HBV_NP ._SENT There_EX have_VBP been_VBN previous_JJ reports_NNS of_IN successful_JJ in_IN vitro_NN infection_NN of_IN primary_JJ Tupaia_NP hepatocytes_NNS with_IN HBV_NP or_CC hepatitis_NP delta_NN virus_NN ,_, but_CC details_NNS of_IN the_DT viral_JJ attachment_NN and_CC neutralization_NN by_IN specific_JJ antibodies_NNS have_VBP not_RB yet_RB been_VBN described_VBN ._SENT Furthermore_RB ,_, the_DT methods_NNS used_VBN to_TO detect_VB infection_NN were_VBD relatively_RB insensitive_JJ semiquantitative_JJ hybridization_NN techniques_NNS for_IN HBV_NP cccDNA_NP and_CC HBV_NP mRNA_NP ._SENT We_PP have_VBP developed_VBN highly_RB sensitive_JJ PCR_NP protocols_NNS for_IN cccDNA_NN and_CC mRNA_NN ,_, and_CC furthermore_RB ,_, we_PP used_VBD de_NP novo_NP HBeAg_NP or_CC HBsAg_NP production_NN as_IN a_DT marker_NN of_IN successful_JJ infection_NN ._SENT More_RBR sensitive_JJ detection_NN of_IN infection_NN allows_VBZ the_DT use_NN of_IN fewer_JJR hepatocytes_NNS ,_, which_WDT are_VBP available_JJ only_RB in_IN limited_JJ amounts_NNS ._SENT Similar_JJ to_TO what_WP Kock_NP et_FW al._FW reported_VBN ,_, we_PP also_RB achieved_VBD our_PP$ best_JJS results_NNS with_IN purified_VBN HBV_NP particles_NNS instead_RB of_IN whole_JJ serum_NN ._SENT As_IN expected_VBN ,_, HBeAg_NP and_CC HBsAg_NP production_NN increased_VBN with_IN increasing_VBG concentration_NN of_IN the_DT input_NN virus_NN ._SENT A_DT ratio_NN of_IN 1_CD ge/hepatocyte_NN was_VBD the_DT minimum_NN for_IN establishing_VBG a_DT detectable_JJ infection_NN ._SENT The_DT highest_JJS levels_NNS of_IN secreted_VBN viral_JJ antigens_NNS resulted_VBN from_IN a_DT ratio_NN of_IN 100_CD ge/hepatocyte_NN ,_, while_IN at_IN 1,000_CD ge/hepatocyte_NN ,_, no_DT increase_NN in_IN HBsAg_NP and_CC HBeAg_NP beyond_IN that_WDT obtained_VBD with_IN the_DT 100-ge/hepatocyte_JJ input_NN was_VBD detected_VBN ._SENT HBV_NP cccDNA_NN levels_NNS showed_VBD the_DT strongest_JJS increase_NN at_IN 10-_CD to_TO 100-ge/hepatocyte_JJ viral_JJ input_NN ._SENT On_IN the_DT other_JJ hand_NN ,_, the_DT total_JJ HBV_NP mRNA_NN content_NN steadily_RB increased_VBN with_IN 1_CD to_TO 1,000_CD input_NN virus_NN ge/hepatocyte_NN ._SENT The_DT reason_NN for_IN this_DT difference_NN among_IN HBV_NP cccDNA_NP ,_, mRNA_NP ,_, and_CC protein_NN production_NN is_VBZ at_IN present_JJ unclear_JJ ._SENT The_DT specificity_NN of_IN the_DT viral_JJ attachment_NN and_CC uptake_NN leading_VBG to_TO infection_NN was_VBD shown_VBN by_IN the_DT use_NN of_IN several_JJ MAbs_NNS against_IN the_DT HBs_NP proteins_NNS ._SENT LHBs_NP is_VBZ preferentially_RB localized_VBN on_IN HBV_NP particles_NNS ._SENT Its_PP$ pre-S1_JJ domain_NN plays_VBZ an_DT important_JJ role_NN during_IN attachment_NN to_TO a_DT liver_NN receptor(s)_NN ._SENT Furthermore_RB ,_, antibodies_NNS raised_VBD against_IN a_DT pre-S1_JJ peptide_NN (_( amino_NN acids_NNS 21_CD to_TO 47_CD )_) neutralized_VBD HBV_NP infection_NN of_IN chimpanzees_NNS ._SENT The_DT pre-S1_JJ antibody_NN used_VBN in_IN this_DT study_NN (_( MA18/7_JJ )_) neutralized_VBN HBV_NP infection_NN of_IN primary_JJ Tupaia_NP hepatocytes_NNS by_IN binding_VBG to_TO a_DT pre-S1_JJ epitope_NN that_WDT overlaps_VBZ with_IN the_DT species_NN specificity-determining_NN region_NN of_IN HBV_NP using_VBG primary_JJ human_JJ hepatocytes_NNS ._SENT These_DT data_NNS support_VBP the_DT conclusion_NN that_IN HBV_NP uses_VBZ homologous_JJ pre-S1_JJ receptor_NN systems_NNS on_IN human_JJ and_CC Tupaia_NP hepatocytes_NNS for_IN the_DT infection_NN process_NN ._SENT Although_IN the_DT MHBs_NP protein_NN is_VBZ not_RB essential_JJ for_IN infection_NN ,_, peptides_NNS with_IN the_DT N-terminal_JJ half_NN of_IN pre-S2_NN were_VBD found_VBN to_TO induce_VB protective_JJ immunity_NN and_CC neutralizing_VBG antibodies_NNS ._SENT Furthermore_RB ,_, a_DT MAb_NP recognizing_VBG amino_NN acids_NNS 13_CD to_TO 24_CD of_IN pre-S2_NN has_VBZ been_VBN reported_VBN to_TO neutralize_VB infection_NN of_IN primary_JJ human_JJ hepatocytes_NNS ._SENT Indeed_RB ,_, in_IN our_PP$ study_NN ,_, MAbs_NNS against_IN this_DT region_NN (_( 2-11B1_JJ and_CC S26_NP )_) also_RB showed_VBD strong_JJ but_CC incomplete_JJ neutralizing_VBG potential_NN ,_, and_CC the_DT cccDNA_NN contents_NNS of_IN the_DT inoculated_VBN cultures_NNS dropped_VBD below_IN the_DT detection_NN limit_NN ._SENT Unfortunately_RB ,_, Ryu_NP et_FW al._FW used_JJ detection_NN of_IN cccDNA_NN by_IN Southern_NP blotting_VBG as_IN a_DT readout_NN ,_, which_WDT is_VBZ certainly_RB much_RB less_RBR sensitive_JJ than_IN the_DT techniques_NNS used_VBN in_IN this_DT study_NN ._SENT In_IN our_PP$ system_NN ,_, we_PP could_MD show_VB that_DT mRNA_NN was_VBD still_RB detectable_JJ ,_, indicating_VBG active_JJ gene_NN expression_NN and_CC resulting_VBG in_IN HBeAg_NP and_CC HBsAg_NP secretion_NN ,_, although_IN reduced_VBN by_IN a_DT factor_NN of_IN 30_CD to_TO 100_CD in_IN comparison_NN to_TO the_DT control_NN infection_NN ._SENT Thus_RB ,_, none_NN of_IN the_DT pre-S2-specific_JJ antibodies_NNS had_VBD the_DT potential_NN to_TO completely_RB neutralize_VB infection_NN like_IN the_DT pre-S1-binding_JJ MAb_NP MA18/7_NP ,_, the_DT conformation-dependent_JJ S_NP antibody_NN C20/2_NP ,_, or_CC the_DT polyclonal_JJ anti-HBs_NNS serum_NN ._SENT Although_IN MAb_NP Q19/10_NP binds_VBZ strongly_RB to_TO the_DT N-terminal_JJ region_NN of_IN pre-S2_NN ,_, it_PP had_VBD the_DT lowest_JJS neutralization_NN potential_NN of_IN all_DT IgG_NP class_NN MAbs_NNS binding_VBG to_TO this_DT domain_NN ._SENT Binding_VBG of_IN MAb_NP Q19/10_NP to_TO pre-S2_JJ amino_NN acids_NNS 1_CD to_TO 6_CD is_VBZ glycan_NN dependent_JJ ,_, and_CC removal_NN of_IN this_DT glycan_NN by_IN peptide_NN N-glycosidase_NN F_NN results_NNS in_IN complete_JJ loss_NN of_IN reactivity_NN ._SENT While_IN the_DT pre-S2_JJ domain_NN is_VBZ present_JJ in_IN both_DT LHBs_NP and_CC MHBs_NP ,_, only_RB the_DT pre-S2_JJ domain_NN of_IN MHBs_NP is_VBZ glycosylated_JJ with_IN a_DT complex_JJ diantennary_JJ glycan_NN at_IN Asn_NP 4_CD ._SENT In_IN LHBs_NP ,_, the_DT pre-S2_JJ domain_NN remains_VBZ unglycosylated_JJ at_IN Asn_NP 4_CD due_JJ to_TO its_PP$ different_JJ topology_NN at_IN the_DT endoplasmic_JJ reticulum_NN ._SENT Therefore_RB ,_, MAb_NP Q19/10_NP binds_VBZ only_RB to_TO the_DT N-glycosylated_JJ pre-S2_JJ region_NN of_IN MHBs_NP but_CC not_RB to_TO LHBs_NP ._SENT Possibly_RB ,_, the_DT stronger_JJR neutralizing_VBG potential_JJ of_IN some_DT pre-S2-specific_JJ antibodies_NNS used_VBN in_IN this_DT study_NN resulted_VBN from_IN binding_VBG to_TO the_DT pre-S2_JJ domain_NN of_IN LHBs_NP ._SENT This_DT possibility_NN is_VBZ in_IN agreement_NN with_IN the_DT nonessentiality_NN of_IN MHBs_NNS for_IN infectivity_NN ._SENT Although_IN no_DT role_NN for_IN pre-S2_JJ protein_NN sequences_NNS has_VBZ been_VBN convincingly_RB proven_VBN for_IN the_DT attachment_NN and_CC entry_NN of_IN HBV_NP ,_, binding_VBG of_IN antibodies_NNS to_TO the_DT amino_NN acid_NN sequence_NN 5_CD to_TO 17_CD may_MD impair_VB attachment_NN or_CC entry_NN ._SENT It_PP is_VBZ noteworthy_JJ that_IN this_DT region_NN of_IN pre-S2_JJ binds_NNS modified_VBN human_JJ serum_NN albumin_NN ,_, which_WDT has_VBZ been_VBN postulated_VBN to_TO mediate_VB indirect_JJ binding_NN to_TO hepatocytes_NNS ._SENT Our_PP$ data_NNS show_VBP that_IN the_DT system_NN is_VBZ feasible_JJ for_IN the_DT assay_NN of_IN neutralizing_VBG anti-HBV_NP antibodies_NNS ._SENT Until_IN now_RB ,_, very_RB few_JJ neutralizing_VBG studies_NNS of_IN anti-HBV_NP antibodies_NNS have_VBP been_VBN done_VBN because_IN they_PP required_VBD either_DT chimpanzees_NNS or_CC primary_JJ human_JJ hepatocytes_NNS ._SENT However_RB ,_, the_DT increasing_VBG appearance_NN of_IN escape_NN mutants_NNS in_IN the_DT S_NP gene_NN after_IN vaccination_NN with_IN SHBs_NP antigen_NN or_CC treatment_NN with_IN HBV_NP immune_JJ globulin_NN highlights_VBZ the_DT need_NN for_IN feasible_JJ neutralization_NN assays_NNS ._SENT In_IN this_DT respect_NN ,_, the_DT predominant_JJ role_NN of_IN pre-S1_JJ antibodies_NNS in_IN neutralization_NN of_IN HBV_NP infectivity_NN should_MD lead_VB to_TO more_JJR attention_NN in_IN strategies_NNS for_IN control_NN and_CC prevention_NN of_IN HBV_NP ._SENT Currently_RB ,_, SHBs_NP is_VBZ the_DT only_JJ component_NN of_IN the_DT most_RBS widely_RB used_VBN vaccines_NNS ._SENT One_CD licensed_JJ vaccine_NN on_IN the_DT market_NN also_RB contains_VBZ MHBs_NNS ,_, although_IN the_DT immunogenicity_NN of_IN the_DT pre-S2_JJ sequence_NN of_IN this_DT vaccine_NN appeared_VBD weak_JJ in_IN humans_NNS ._SENT There_EX is_VBZ at_IN present_NN no_DT vaccine_NN on_IN the_DT market_NN which_WDT contains_VBZ the_DT pre-S1_JJ neutralizing_VBG epitopes_NNS ,_, but_CC two_CD vaccines_NNS have_VBP already_RB undergone_VBN successful_JJ clinical_JJ evaluation_NN ._SENT Whether_IN these_DT vaccines_NNS induce_VB protective_JJ levels_NNS of_IN anti-pre-S1_JJ antibodies_NNS is_VBZ unknown_JJ ._SENT Infection_NN of_IN primary_JJ Tupaia_NP hepatocytes_NNS seems_VBZ to_TO be_VB dependent_JJ only_RB upon_IN LHBs_NP and_CC SHBs_NP ,_, as_RB in_IN the_DT human_JJ system_NN ._SENT Unexpectedly_RB ,_, by_IN the_DT use_NN of_IN subviral_JJ particles_NNS ,_, >70_JJ %_NN of_IN the_DT primary_JJ Tupaia_NP hepatocytes_NNS were_VBD capable_JJ of_IN specific_JJ binding_NN to_TO pre-S1-rich_NP HBsAg_NP ._SENT Interestingly_RB ,_, the_DT bound_JJ HBsAg_NP was_VBD not_RB evenly_RB distributed_VBN but_CC localized_VBN to_TO distinct_JJ membrane_NN areas_NNS of_IN hepatocytes_NNS ,_, often_RB associated_VBN with_IN special_JJ membrane_NN structures_NNS like_IN lamellipodi_NNS or_CC microvilli_NNS ._SENT Since_IN the_DT sinusoidal_JJ side_NN of_IN hepatocytes_NNS in_IN the_DT liver_NN is_VBZ also_RB heavily_RB covered_VBN with_IN microvilli_NNS ,_, these_DT structures_NNS may_MD be_VB enriched_VBN in_IN HBV_NP receptors_NNS ._SENT Furthermore_RB ,_, many_JJ hepatocytes_NNS showed_VBD signs_NNS of_IN HBsAg_NP uptake_NN and_CC transport_NN to_TO perinuclear_NN rather_RB than_IN to_TO perimembranous_JJ sites_NNS ._SENT The_DT staining_VBG strongly_RB decreased_VBN within_IN 2_CD h_NN after_IN uptake_NN ,_, which_WDT may_MD be_VB due_JJ to_TO destruction_NN of_IN the_DT HBsAg_NP conformational_JJ epitope_NN by_IN reduction_NN in_IN an_DT endosomal_JJ or_CC lysosomal_JJ compartment_NN and_CC nonreactivity_NN with_IN anti-HBs_NNS ._SENT A_DT similar_JJ uptake_NN phenomenon_NN has_VBZ been_VBN observed_VBN with_IN primary_JJ human_JJ hepatocytes_NNS and_CC fluorescently_RB labeled_VBN subviral_JJ particles_NNS from_IN the_DT same_JJ patient_NN using_VBG confocal_JJ microscopy_NN imaging_NN ._SENT Until_IN now_RB ,_, fluorescence_NN microscopy_NN has_VBZ unfortunately_RB not_RB been_VBN applicable_JJ in_IN our_PP$ studies_NNS of_IN Tupaia_NP hepatocytes_NNS due_JJ to_TO strong_JJ autofluorescence_NN ._SENT Thus_RB ,_, the_DT pathway_NN of_IN HBsAg_NP uptake_NN to_TO Tupaia_NP hepatocytes_NNS is_VBZ unknown_JJ and_CC needs_VBZ to_TO be_VB elucidated_VBN ._SENT Besides_IN the_DT strong_JJ binding_NN and_CC uptake_NN of_IN HBsAg_NP ,_, only_RB a_DT portion_NN of_IN primary_JJ Tupaia_NP hepatocytes_NNS could_MD be_VB infected_VBN to_TO the_DT point_NN that_IN they_PP were_VBD actively_RB producing_VBG HBsAg_NP at_IN levels_NNS detectable_JJ by_IN i_NP 